Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.
Epistemonikos ID: a345f0a85fc04f2de99a9bcf472f1812c8f5a464
First added on: May 08, 2024